The non-alcoholic fatty liver disease market size is supposed to grow during the forecast period owing to the expected launch of novel emerging therapies, which shall fuel the growth of the non-alcoholic fatty liver disease market during the forecast period, i.e., 2023–2032.

由于预计将推出新的新兴疗法，预计非酒精性脂肪肝市场规模将在预测期内增长，这将在预测期（即2023-2032年）推动非酒精性脂肪肝市场的增长。

LAS VEGAS , Jan. 22, 2024 /PRNewswire/ -- DelveInsight's Non-Alcoholic Fatty Liver Disease Market Insights report includes a comprehensive understanding of current treatment practices, NAFLD emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan]..

拉斯维加斯，2024年1月22日/PRNewswire/--DelveInsight的非酒精性脂肪肝市场洞察报告包括对当前治疗实践，NAFLD新兴药物，个体疗法的市场份额以及2019年至2032年的当前和预测市场规模的全面了解，分为7MM[美国、EU4（德国、法国、意大利和西班牙）、英国和日本]。。

Key Takeaways from the Non-Alcoholic Fatty Liver Disease Market Report

非酒精性脂肪肝市场报告的主要收获

According to DelveInsight's analysis, the market size for NAFLD across the 7MM is expected to grow with a significant CAGR by 2032.

根据DelveInsight的分析，预计到2032年，NAFLD在7MM范围内的市场规模将以显着的复合年增长率增长。

DelveInsight's analysis reveals that in the US most cases of NAFLD are found to be in between 40-60 years old adults compared to the 16-39 age group in 2022.

DelveInsight的分析显示，在美国，与2022年的16-39岁年龄组相比，大多数NAFLD病例发生在40-60岁之间。

Leading non-alcoholic fatty liver disease companies such as MediciNova, Eli Lilly and Company, AstraZeneca, Inventiva Pharma, Oasis Pharmaceuticals, LLC, Madrigal Pharmaceuticals, Inc., BioMarin Pharmaceutical, GlaxoSmithKline, Zydus Therapeutics Inc., Akero Therapeutics, Inc, Pfizer, Boehringer Ingelheim, Neuraly, Inc., Merck Sharp & Dohme LLC, Rivus Pharmaceuticals, Inc., Hepion Pharmaceuticals, Inc., and others are developing novel NAFLD drugs that can be available in the NAFLD market in the coming years..

领先的非酒精性脂肪性肝病公司，如MediciNova、Eli Lilly and Company、AstraZeneca、Inventiva Pharma、Oasis Pharmaceuticals，LLC、Madrigal Pharmaceuticals，Inc.、BioMarin Pharmaceuticals、GlaxoSmithKline、Zydus Therapeutics Inc.、Akero Therapeutics，Inc.、辉瑞、勃林格殷格翰、Neuraly，Inc.、默克Sharp&Dohme LLC、Rivus Pharmaceuticals，Inc。，Hepion Pharmaceuticals，Inc.和其他公司正在开发新的NAFLD药物，这些药物可以在未来几年的NAFLD市场上买到。。

The promising non-alcoholic fatty liver disease therapies in the pipeline include MN-001, LY3885125, AZD7503, Lanifibranor, OA-235i, Resmetirom, BMN 255, GSK4532990, Saroglitazar Magnesium 4 mg Tablet, Efruxifermin, PF-06865571, BI 3006337, DD01, Efinopegdutide, HU6, Rencofilstat, and others.

正在开发的有前途的非酒精性脂肪肝治疗方法包括MN-001，LY3885125，AZD7503，Lanifibranor，OA-235i，Resmetirom，BMN 255，GSK4532990，Saroglitazar镁4 mg片剂，Efruxifermin，PF-06865571，BI 3006337，DD01，Efinopegdutide，HU6，Rencofilstat等。

Discover which therapies are expected to grab the major NAFLD market share @ Non-Alcoholic Fatty Liver Disease Market Report

发现哪些疗法有望在非酒精性脂肪性肝病市场报告中占据主要的NAFLD市场份额

Non-Alcoholic Fatty Liver Disease Overview

非酒精性脂肪性肝病概述

Non-alcoholic fatty liver disease (NAFLD) is a comprehensive term encompassing a range of liver conditions involving the accumulation of fat, spanning from basic steatosis to more advanced stages characterized by associated hepatitis, fibrosis, cirrhosis, and, in some instances, hepatocellular carcinoma.

非酒精性脂肪性肝病（NAFLD）是一个综合性术语，涵盖了一系列涉及脂肪积累的肝脏疾病，从基本脂肪变性到以肝炎，纤维化，肝硬化为特征的更晚期阶段，在某些情况下还包括肝细胞癌。

While many individuals may harbor liver fat without evident symptoms or complications, in certain cases, the deposited fat triggers inflammation, leading to cellular damage and impaired liver functionality. The precise cause of NAFLD remains unknown, but it is often associated with factors such as overweight or obesity, type 2 diabetes or pre-diabetes, abnormal lipid levels in the blood, among others..

虽然许多人可能携带肝脏脂肪而没有明显的症状或并发症，但在某些情况下，沉积的脂肪会引发炎症，导致细胞损伤和肝脏功能受损。NAFLD的确切原因尚不清楚，但它通常与超重或肥胖，2型糖尿病或糖尿病前期，血液中脂质水平异常等因素有关。。

For most individuals, there are no discernible symptoms, but in some cases, inflammation from the fat can damage liver cells, hindering the organ's proper function. The likelihood of developing NAFLD, whether in the form of simple fatty liver or non-alcoholic steatohepatitis (NASH), increases with factors like excess weight, type 2 diabetes or pre-diabetes, and abnormal lipid levels in the blood.

对于大多数人来说，没有明显的症状，但在某些情况下，脂肪引起的炎症会损害肝细胞，阻碍器官的正常功能。无论是单纯性脂肪肝还是非酒精性脂肪性肝炎（NASH），发生NAFLD的可能性随着体重超重、2型糖尿病或糖尿病前期以及血液中脂质水平异常等因素的增加而增加。

A definitive diagnosis of NASH can only be established through a liver biopsy, which not only confirms the condition but also provides insights into the severity of the disease. Importantly, liver biopsy is more adept at detecting fibrosis at earlier stages than elastography..

NASH的明确诊断只能通过肝活检来确定，这不仅可以确认病情，还可以提供对疾病严重程度的见解。重要的是，肝活检比弹性成像更善于在早期检测纤维化。。

Non-Alcoholic Fatty Liver Disease Epidemiology Segmentation

非酒精性脂肪肝流行病学细分

The NAFLD epidemiology section provides insights into the historical and current NAFLD patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders.

NAFLD流行病学部分提供了对历史和当前NAFLD患者库的见解，并预测了7MM的趋势。通过探索大量研究和关键意见领袖的观点，它有助于识别当前和预测患者趋势的原因。

The NAFLD market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

NAFLD市场报告提供了2019-2032年研究期间7MM的流行病学分析，分为：

Total NAFLD Prevalent Cases

NAFLD流行病例总数

NAFLD Gender-specific Prevalent Cases

NAFLD性别特异性流行病例

NAFLD Age-specific Prevalent Cases

NAFLD年龄特异性流行病例

NAFLD Stage-specific Prevalent Cases

NAFLD阶段特异性流行病例

NAFLD Diagnosed and Treatable Cases

NAFLD诊断和治疗病例

Non-Alcoholic Fatty Liver Disease Treatment Market

非酒精性脂肪肝治疗市场

Currently, there are no approved treatments for NAFLD by regulatory agencies such as the FDA, EMA, or PMDA. However, researchers are exploring potential medications to address this condition. The primary approach for treating NAFLD involves lifestyle changes, including adjustments to diet and exercise.

目前，没有FDA，EMA或PMDA等监管机构批准的NAFLD治疗方法。然而，研究人员正在探索潜在的药物来解决这种情况。治疗NAFLD的主要方法是改变生活方式，包括调整饮食和锻炼。

In addition to these modifications, alternative options for treating non-alcoholic steatohepatitis (NASH) have involved the off-label use of vitamin E and anti-diabetes medications like pioglitazone and liraglutide. The NAFLD practice guidance from the American Association for the Study of Liver Diseases (AASLD) suggests considering the off-label use of vitamin E for non-cirrhotic, non-diabetic individuals with biopsy-confirmed NASH and pioglitazone for managing diabetic patients with biopsy-confirmed NASH..

除了这些修改之外，治疗非酒精性脂肪性肝炎（NASH）的替代选择还涉及维生素E和抗糖尿病药物（如吡格列酮和利拉鲁肽）的标签外使用。美国肝病研究协会（AASLD）的NAFLD实践指南建议，对于活检证实为NASH的非肝硬化非糖尿病患者和吡格列酮治疗活检证实为NASH的糖尿病患者，考虑非标签使用维生素E。。

Vitamin E, recognized for its antioxidant properties, is regarded as an initial pharmacological approach in addressing NASH, particularly when dietary and lifestyle adjustments prove inadequate. Agents with antifibrotic properties can halt the advancement from liver fibrosis and NAFLD to fibrotic NASH.

维生素E以其抗氧化特性而闻名，被认为是解决NASH的最初药理学方法，特别是当饮食和生活方式调整证明不足时。具有抗纤维化特性的药物可以阻止肝纤维化和NAFLD向纤维化NASH的发展。

While the impact of pioglitazone (an anti-diabetic agent) on NASH histology in individuals with T2D has been thoroughly established, certain apprehensions linger, including issues like weight gain, fluid retention, cancer risk, and susceptibility to bone fractures..

虽然吡格列酮（一种抗糖尿病药物）对T2D患者NASH组织学的影响已经完全确定，但某些担忧仍然存在，包括体重增加，体液潴留，癌症风险和骨折易感性等问题。。

Additionally, other focuses for treating NAFLD and NASH include G protein-coupled receptors (GPCRs), estrogen-related receptor alpha (ERRα), bone morphogenetic proteins (BMPs), and KLFs. Bariatric surgery, also known as weight loss surgery, is considered the most efficient method to address obesity and diabetes.

此外，治疗NAFLD和NASH的其他重点包括G蛋白偶联受体（GPCR），雌激素相关受体α（ERRα），骨形态发生蛋白（BMP）和KLF。减肥手术，也称为减肥手术，被认为是解决肥胖和糖尿病的最有效方法。

This procedure works by decreasing food absorption and adjusting gut hormone secretion and metabolic issues..

这个过程通过减少食物吸收和调节肠道激素分泌和代谢问题来起作用。。

To know more about NAFLD treatment guidelines, visit @ Non-Alcoholic Fatty Liver Disease Management

要了解更多有关NAFLD治疗指南的信息，请访问@非酒精性脂肪肝疾病管理

Non-Alcoholic Fatty Liver Disease Pipeline Therapies and Key Companies

非酒精性脂肪肝管道治疗和关键公司

MN-001: MediciNova

MN-001：MediciNova

LY3885125: Eli Lilly and Company

LY3885125：礼来公司

AZD7503: AstraZeneca

AZD7503:阿斯利康

Lanifibranor: Inventiva Pharma

Lanifabranor:Inventiva Pharma

OA-235i: Oasis Pharmaceuticals, LLC

OA-235i：绿洲制药有限责任公司

Resmetirom: Madrigal Pharmaceuticals, Inc.

研究单位：马德里加尔制药公司，股份有限公司。

BMN 255: BioMarin Pharmaceutical

BMN 255：生物素制药

GSK4532990: GlaxoSmithKline

葛兰素史克GSK4532990

Saroglitazar Magnesium 4 mg Tablet: Zydus Therapeutics Inc.

Saroglitazar镁4 mg片剂：Zydus Therapeutics股份有限公司。

Efruxifermin: Akero Therapeutics, Inc

艾福乐明：Akero Therapeutics，股份有限公司。

PF-06865571: Pfizer

PF-06865571：辉瑞

BI 3006337: Boehringer Ingelheim

BI 3006337:Boehringer Ingelheim

DD01: Neuraly, Inc.

DD01：神经，股份有限公司。

Efinopegdutide: Merck Sharp & Dohme LLC

Efinopegdutide:Merck Sharp&Dohme LLC

HU6: Rivus Pharmaceuticals, Inc.

HU6:Rivus Pharmaceuticals，股份有限公司。

Rencofilstat: Hepion Pharmaceuticals, Inc.

Rencofilstat：Hepion Pharmaceuticals，Inc。

Learn more about the FDA-approved drugs for NAFLD @ Drugs for Non-Alcoholic Fatty Liver Disease Treatment

了解更多有关FDA批准的NAFLD药物@非酒精性脂肪肝治疗药物的信息

Non-Alcoholic Fatty Liver Disease Market Dynamics

非酒精性脂肪性肝病市场动态

The dynamics of the non-alcoholic fatty liver disease market are expected to change in the coming years. The increasing research activities and numerous ongoing clinical trials for NASH indicate a growing number of drug developments that are poised to strengthen the NAFLD market, presenting lucrative opportunities for NAFLD market growth in the 7MM due to the substantial presence of a large pool of patients suffering from NASH..

预计未来几年非酒精性脂肪性肝病市场的动态将发生变化。越来越多的NASH研究活动和大量正在进行的临床试验表明，越来越多的药物开发准备加强NAFLD市场，由于大量患有NASH的患者的存在，为7MM的NAFLD市场增长提供了有利可图的机会。。

Furthermore, as many potential therapies are being investigated for the treatment of NAFLD, and it is safe to predict that the treatment space will significantly impact the NAFLD market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate are expected to drive the growth of the NAFLD market in the 7MM..

此外，由于正在研究许多治疗NAFLD的潜在疗法，因此可以安全地预测，在预测期间，治疗空间将对NAFLD市场产生重大影响。此外，预期引入具有改善疗效和进一步提高诊断率的新兴疗法，预计将推动7MM NAFLD市场的增长。。

However several factors may impede the growth of the non-alcoholic fatty liver disease market. The diagnosis of NASH involves an invasive procedure, and the launch of generics will pose a threat to new emerging therapies due to their cost-effectiveness. Moreover, NAFLD treatment poses a significant economic burden and disrupts patients' overall well-being and QOL.

然而，有几个因素可能会阻碍非酒精性脂肪性肝病市场的增长。NASH的诊断涉及侵入性手术，仿制药的推出将对新兴疗法构成威胁，因为它们具有成本效益。此外，NAFLD治疗带来了巨大的经济负担，并破坏了患者的整体幸福感和生活质量。

Furthermore, the NAFLD market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the NAFLD market growth..

此外，NAFLD市场的增长可能会被新兴疗法的失败和停止，无法负担的定价，市场准入和报销问题以及医疗保健专家的短缺所抵消。此外，未确诊，未报告的病例以及对该疾病的不了解也可能影响NAFLD市场的增长。。

Non-Alcoholic Fatty Liver Disease Market Report Metrics

非酒精性脂肪性肝病市场报告指标

Details

详细信息

Study Period

研究期间

2019–2032

2019–2032

Coverage

覆盖范围

7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan].

7MM[美国、欧盟4国（德国、法国、意大利和西班牙）以及英国和日本]。

Key Non-Alcoholic Fatty Liver Disease Companies

主要非酒精性脂肪性肝病公司

MediciNova, Eli Lilly and Company, AstraZeneca, Inventiva Pharma, Oasis Pharmaceuticals, LLC, Madrigal Pharmaceuticals, Inc., BioMarin Pharmaceutical, GlaxoSmithKline, Zydus Therapeutics Inc., Akero Therapeutics, Inc, Pfizer, Boehringer Ingelheim, Neuraly, Inc., Merck Sharp & Dohme LLC, Rivus Pharmaceuticals, Inc., Hepion Pharmaceuticals, Inc., and others .

MediciNova、Eli Lilly and Company、AstraZeneca、Inventiva Pharma、Oasis Pharmaceuticals，LLC、Madrigal Pharmacecals，股份有限公司、BioMarin Pharmacecal、GlaxoSmithKline、Zydus Therapeutics股份有限公司、Akero Therapeucs，Inc、Pfizer、Boehringer Ingelheim、Neuraly，股份有限公司、Merck Sharp&Dohme LLC、Rivus Pharmacermaceutical，股份有限公司、Hepion Pharmacements，股份有限公司等

Key Pipeline Non-Alcoholic Fatty Liver Disease Therapies

关键管道非酒精性脂肪肝治疗

MN-001, LY3885125, AZD7503, Lanifibranor, OA-235i, Resmetirom, BMN 255, GSK4532990, Saroglitazar Magnesium 4 mg Tablet, Efruxifermin, PF-06865571, BI 3006337, DD01, Efinopegdutide, HU6, Rencofilstat, and others

MN-001、LY38885125、AZD7503、Lanifibranor、OA-235i、Resmetrom、BMN 255、GSK4532990、Saroglitazar 4 mg镁片、依呋昔费明、PF-06865571、BI 3006337、DD01、依非诺普肽、HU6、Rencofilstat等

Scope of the Non-Alcoholic Fatty Liver Disease Market Report

非酒精性脂肪性肝病市场报告范围

Therapeutic Assessment: Non-Alcoholic Fatty Liver Disease current marketed and emerging therapies

治疗评估：非酒精性脂肪肝目前上市和新兴疗法

Non-Alcoholic Fatty Liver Disease Market Dynamics: Key Market Forecast Assumptions of Emerging Non-Alcoholic Fatty Liver Disease Drugs and Market Outlook

非酒精性脂肪性肝病市场动态：新兴非酒精性脂肪性肝病药物的关键市场预测假设和市场前景

Competitive Intelligence Analysis: SWOT analysis and Market entry strategies

竞争情报分析：SWOT分析与市场进入策略

Unmet Needs, KOL's views, Analyst's views, Non-Alcoholic Fatty Liver Disease Market Access and Reimbursement

未满足的需求、KOL的观点、分析师的观点、非酒精性脂肪肝的市场准入和报销

Discover more about NAFLD drugs in development @ Non-Alcoholic Fatty Liver Disease Clinical Trials

更多关于NAFLD药物开发@非酒精性脂肪肝临床试验的信息

Table of Contents

目录

1.

1.

Non-Alcoholic Fatty Liver Disease Key Insights

非酒精性脂肪性肝病关键见解

2.

2.

Non-Alcoholic Fatty Liver Disease Report Introduction

非酒精性脂肪性肝病报告简介

3.

3.

Non-Alcoholic Fatty Liver Disease Overview at a Glance

非酒精性脂肪性肝病概述

4.

4.

Non-Alcoholic Fatty Liver Disease Executive Summary

非酒精性脂肪性肝病执行摘要

5

5

Non-Alcoholic Fatty Liver Disease Key Events

非酒精性脂肪肝关键事件

6

6

Epidemiology and Market Forecast Methodology

流行病学和市场预测方法

6.

6.

Disease Background and Overview

疾病背景和概述

7.

7.

Non-Alcoholic Fatty Liver Disease Treatment and Management

非酒精性脂肪肝的治疗与管理

8.

8.

Non-Alcoholic Fatty Liver Disease Guidelines

非酒精性脂肪肝指南

9.

9.

Non-Alcoholic Fatty Liver Disease Epidemiology and Patient Population

非酒精性脂肪肝流行病学和患者人群

10.

10.

Patient Journey

患者旅程

11.

11.

Key Endpoints in Non-Alcoholic Fatty Liver Disease

非酒精性脂肪性肝病的关键终点

12.

12.

Non-Alcoholic Fatty Liver Disease Marketed Drugs

非酒精性脂肪肝上市药物

13.

13.

Non-Alcoholic Fatty Liver Disease Emerging Drugs

非酒精性脂肪肝新兴药物

14.

14.

7MM Non-Alcoholic Fatty Liver Disease Market Analysis

7MM非酒精性脂肪性肝病市场分析

15.

15.

Market Access and Reimbursement

市场准入和报销

16.

16.

KOL Views

KOL Views

17.

17.

Unmet Needs

未满足的需求

18.

18.

SWOT Analysis

SWOT分析

19.

19.

Appendix

附录

20.

20.

DelveInsight Capabilities

DelveInsight功能

21.

21.

Disclaimer

免责声明

22.

22.

About DelveInsight

关于DelveInsight

Related Reports

相关报告

Non-Alcoholic Fatty Liver Disease Pipeline

非酒精性脂肪性肝病管道

Non-Alcoholic Fatty Liver Disease Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key NAFLD companies, including BeiGene, Inventiva Pharma, Cirius Therapeutics, Madrigal Pharma, Novo Nordisk, Galmed Pharmaceuticals, AstraZeneca, Galectin Therapeutics, Viking Therapeutics, Dr.

非酒精性脂肪肝疾病管道洞察-2023年报告提供了有关管道景观，管道药物概况（包括临床和非临床阶段产品）以及关键NAFLD公司（包括BeiGene，Inventiva Pharma，Cirius Therapeutics，Madrigal Pharma，Novo Nordisk，Galmed Pharmaceuticals，AstraZeneca，Galectin Therapeutics，Viking Therapeutics博士。

Falk Pharma GmbH, Sagimet Biosciences, Eli Lilly and Company, Terns Pharmaceuticals, Sinew Pharma, Novartis Pharmaceuticals, Afimmune, Poxel SA, AngioLab, Pfizer, Oramed Pharmaceuticals, Can Fite Biopharma, MediciNova, Metacrine, Inc., Lipocine, Inc., CytoDyn, Inc., Alnylam Pharmaceuticals, Inc., Mitsubishi Tanabe Pharma, Chemomab Therapeutics, NuSirt Biopharma, HK inno.N, Kowa Pharmaceutical, Ionis Pharmaceuticals, NorthSea Therapeutics, Rivus Pharmaceuticals, Hanmi Pharmaceutical, Hepagene Therapeutics, HighTide Biopharma, Akero Therapeutics, Enanta Pharmaceuticals, Cascade Pharmaceuticals, among others..

Falk Pharma GmbH，Sagimet Biosciences，Eli Lilly and Company，Terns Pharmaceuticals，Sinew Pharma，Novartis Pharmacecals，Afimmuno，Poxel SA，AngioLab，Pfizer，Oramed Pharmacermaceutical，Can-Fite Biopharma，MediciNova，Metacritic，股份有限公司，Lipocine，股份有限公司，CytoDyn，股份有限公司，Alnylam Pharmace，股份有限公司，Mitsubishi Tanabe Pharmas，Chemomab Therapeutics，NuSirt Biopharma。N、 Kowa制药公司、Ionis制药公司、北海制药公司、Rivus制药公司、Hanmi制药公司、Hepagene制药公司、HighTide Biopharma、Akero制药公司、Enanta制药公司、Cascade制药公司等。

Non-Alcoholic Fatty Liver Disease Epidemiology Forecast

非酒精性脂肪肝流行病学预测

Non-Alcoholic Fatty Liver Disease Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted NAFLD epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

《非酒精性脂肪肝流行病学预测-2032年报告》深入了解了该疾病，以及美国、欧盟5国（德国、西班牙、意大利、法国和英国）和日本的历史和预测NAFLD流行病学。

Nonalcoholic Steatohepatitis Market

非酒精性脂肪性肝炎市场

Nonalcoholic Steatohepatitis Market Insight, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key nonalcoholic steatohepatitis companies, including Madrigal Pharmaceuticals, Intercept Pharmaceuticals, Cirius Therapeutics, Novo Nordisk, Inventiva, Galmed Pharmaceuticals, AstraZeneca, Galectin Therapeutics, Viking Therapeutics, Eli Lilly and Company, Terns Pharmaceuticals, Sinew Pharma, 89bio, Inc., Eccogene, Novartis Pharmaceuticals, Poxel SA, AngioLab, Pfizer, Arrowhead Pharma, LG Chem, Redx Pharma, Lipocine, Inc., CytoDyn, Inc., Alnylam Pharmaceuticals, Inc., Chemomab Therapeutics, NuSirt Biopharma, HK inno.

非酒精性脂肪性肝炎市场洞察、流行病学和市场预测-2032年报告深入了解了市场趋势、市场驱动因素、市场障碍以及关键的非酒精性脂肪性肝炎公司，包括Madrigal Pharmaceuticals、Intercept Pharmaceuticals、Cirius Therapeutics、Novo Nordisk、Inventiva、Galmed Pharmaceuticals、AstraZeneca、，Galectin Therapeutics，Viking Therapeutics，Eli Lilly and Company，Terns Pharmaceuticals，Sinew Pharma，89bio，Inc.，Eccogene，Novartis Pharmaceuticals，Poxel SA，AngioLab，Pfizer，Arrowhead Pharma，LG Chem，Redx Pharma，Lipocine，Inc.，CytoDyn，Inc.，Alnylam Pharmaceuticals，Inc.，Chemomab Therapeutics，NuSirt Biopharma，HK inno。

N, Aligos Therapeutics, Altimmune, Inc., Kowa Pharmaceutical, Ionis Pharmaceuticals, NorthSea Therapeutics, Rivus Pharmaceuticals, Hanmi Pharmaceutical, Hepagene Therapeutics, HighTide Biopharma, Akero Therapeutics, Merck Sharp & Dohme LLC, Cascade Pharmaceuticals, Hepion Pharmaceuticals, Chipscreen Biosciences, Boston Pharmaceuticals, Bristol-Myers Squibb, Sunshine Lake Pharma, GSK plc., Future Medicine, Gilead Sciences, ENYO Pharma, Histogen, among others..

N、 Aligos Therapeutics、Altimmune，Inc.、Kowa Pharmaceuticals、Ionis Pharmaceuticals、NorthSea Therapeutics、Rivus Pharmaceuticals、Hanmi Pharmaceuticals、Hepagene Therapeutics、HighTide Biopharma、Akero Therapeutics、Merck Sharp&Dohme LLC、Cascade Pharmaceuticals、Hepion Pharmaceuticals、Chipscreen Biosciences、Boston Ph。，未来医学、吉利德科学、恩约制药、Histogen等。。

Nonalcoholic Steatohepatitis Pipeline

非酒精性脂肪性肝炎管道

Nonalcoholic Steatohepatitis Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key nonalcoholic steatohepatitis companies, including Madrigal Pharmaceuticals, Intercept Pharmaceuticals, Cirius Therapeutics, Novo Nordisk, Inventiva, Galmed Pharmaceuticals, AstraZeneca, Galectin Therapeutics, Viking Therapeutics, Eli Lilly and Company, Terns Pharmaceuticals, Sinew Pharma, 89bio, Inc., Eccogene, Novartis Pharmaceuticals, Poxel SA, AngioLab, Pfizer, Arrowhead Pharma, LG Chem, Redx Pharma, Lipocine, Inc., CytoDyn, Inc., Alnylam Pharmaceuticals, Inc., Chemomab Therapeutics, NuSirt Biopharma, HK inno.

非酒精性脂肪性肝炎管道洞察-2022年报告提供了有关管道景观，管道药物概况（包括临床和非临床阶段产品）以及关键非酒精性脂肪性肝炎公司（包括Madrigal Pharmaceuticals，Intercept Pharmaceuticals，Cirius Therapeutics，Novo Nordisk，Inventiva，Galmed Pharmaceuticals，AstraZeneca，Galectin Therapeutics，Viking Therapeutics，Eli Lilly and Company，Terns Pharmaceuticals，Sinew Pharma，89bio，Inc.，Eccogene，Novartis Pharmaceuticals，Poxel SA，AngioLab，Pfizer，Arrowhead Pharma，LG Chem，Redx Pharma，Lipocine，Inc.，CytoDyn，Inc.，Alnylam Pharmaceuticals，Inc.，Chemomab Therapeutics，NuSirt Biopharma，HK inno。

N, Aligos Therapeutics, Altimmune, Inc., Kowa Pharmaceutical, Ionis Pharmaceuticals, NorthSea Therapeutics, Rivus Pharmaceuticals, Hanmi Pharmaceutical, Hepagene Therapeutics, HighTide Biopharma, Akero Therapeutics, Merck Sharp & Dohme LLC, Cascade Pharmaceuticals, Hepion Pharmaceuticals, Chipscreen Biosciences, Boston Pharmaceuticals, Bristol-Myers Squibb, Sunshine Lake Pharma, GSK plc., Future Medicine, Gilead Sciences, ENYO Pharma, Histogen, among others..

N、 Aligos Therapeutics、Altimmune，Inc.、Kowa Pharmaceuticals、Ionis Pharmaceuticals、NorthSea Therapeutics、Rivus Pharmaceuticals、Hanmi Pharmaceuticals、Hepagene Therapeutics、HighTide Biopharma、Akero Therapeutics、Merck Sharp&Dohme LLC、Cascade Pharmaceuticals、Hepion Pharmaceuticals、Chipscreen Biosciences、Boston Ph。，未来医学、吉利德科学、恩约制药、Histogen等。。

About DelveInsight

关于DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve..

DelveInsight是一家专注于生命科学的领先商业顾问和市场研究公司。它通过提供全面的端到端解决方案来提高制药公司的绩效，从而为制药公司提供支持。通过我们基于订阅的平台PharmDelve，轻松访问所有医疗保健和制药市场研究报告。。

Contact UsShruti Thakur [email protected] +91-9650213330www.delveinsight.com

Contact UsShruti Thakur [email protected] +91-9650213330www.delveinsight.com

Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg

标志：https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg

SOURCE DelveInsight Business Research, LLP

来源：DelveInsight Business Research，LLP